
    
      This is a phase I,single center, randomized, double-blind and parallel group clinical trial .
      The primary objective is to assess the pharmacokinetic similarity of single and subcutaneous
      injections of QL1206 or Prolia® in healthy volunteers. The secondary objective are to assess
      the Clinical safety and immunogenicity similarity of single and subcutaneous injections of
      QL1206 or Prolia® in healthy volunteers. Meanwhile，observing the pharmacodynamic similarities
      of QL1206 or Prolia® preliminarily. Subjects would receive a single 60mg（1ml） of QL1206 or
      through subcutaneous injection.
    
  